Gilead Entered into a Multi-Year Collaboration Agreement with Tentarix to Discover and Develop Novel Therapies for Cancer
Shots:
- Under the terms of the agreement, Tentarix will receive up front, an equity investment from Gilead of $66M. Gilead gets an option to acquire up to three select Tentarix subsidiaries containing the programs developed under the collaborations for $80M per subsidiary
- The collaboration will combine Tentarix’s Tentacles platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases & focuses to offer potential therapies to patients
- These molecules can conditionally target immune cells linked to disease pathways without activating other immune cells that might cause adverse outcomes to improve therapeutic benefit and safety
Ref: Businesswire | Image: Gilead
Related News:- Biotheus Entered into a Research Collaboration and License Agreement with BioNTech to Discover Novel Therapies for Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
